Full takeover versus multiple deals?

I think most shareholders, as decrepit and impatient as we all are, can see the travesty that would be if BP were to take us out for only the value of either the canine trials or MND.

My understanding over the years has been that RA would prefer to do separate deals for each application or group of applications for MPL, utilising those proceeds to further fund the pipeline.

My assumption is that there would likely be some small dividend to shareholders after revenues from each deal have been received, yet I have not heard anything precise from the company on this aspect.
Now with Epichem out of the picture, there may have been a change of thinking?

Has anybody heard any different?

This Strategy, however, might not stop any BP from attempting a takeover.

Therefore, it would be up to the shareholders to form a bloc preventing any premature TO from occurring.

What are everybody's thoughts here?